Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib in Metastatic Castration-Resistant Prostate Cancer
NCT04781374Phase 2Withdrawn
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Beth Israel Deaconess Medical Center. Planned start May 2021; status: withdrawn.
02
Drugs
neratinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04781374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781374.